Iovance Biotherapeutics Inc (IOVA)

[jondoeuk]

Preliminary results from a PhII trial, innovaTIL-04, assessing lead candidate LN-145 in patients with recurrent/metastatic/refractory cervical cancer (average of 2.6 prior lines of therapy) showed a 44% ORR (n=12/27) and a DCR of 89% (n=24/27). Eleven of the 12 responders maintained their responses at a median follow-up of 3.5 months. By comparison, the ORR for MRK's Keytruda in second-line cervical cancer is 14%.

New data from Cohort 2 in the PhII innovaTIL-01 trial evaluating Lifileucel in metastatic melanoma patients (average of 3.1 prior lines of therapy) showed an ORR of 38% (n=21/55) and a DCR of 76% (n=42/55). At a median follow-up of 7.4 months, only four responders progressed. Improved responses were observed in 4 patients with longer follow-up.

Also, the first patient has been dosed in IOV-COM-202 trial. This is the first time that IOVA's TIL therapy has been administered in a PD-1/PD-L1 naive patient population.

In addition to the above the company is now working with GNCA* https://www.globenewswire.com/news-release/2019/05/16/1826454/0/en/Genocea-Announces-Research-Collaboration-with-Iovance-to-Explore-Development-of-Neoantigen-Targeted-TIL-Tumor-Infiltrating-Lymphocyte-Products.html

* Some GNCA data https://www.globenewswire.com/news-release/2019/05/16/1826127/0/en/Genocea-Announces-Positive-Interim-Immunogenicity-Data-from-GEN-009-Neoantigen-Vaccine-Phase-1-2a-Clinical-Trial.html